Shan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shan Zhang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Qinghu Bian
Second Hospital of Hebei Medical University
4 shared publicationsZhiqiang Zhang
Second Hospital of Hebei Medical University
4 shared publicationsYanli Li
Department of Anesthesiology, Second Hospital of Hebei Medical University, Shijiazhuang, P.R. China
3 shared publicationsZan Gao
Department of Anesthesiology, Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China
3 shared publicationsDongyang Ma
Department of Anesthesiology, Second Hospital of Hebei Medical University, Shijiazhuang, P.R. China
2 shared publicationsZheng Liu
Department of Anesthesiology, Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China
2 shared publications
Latest Publications
- 1 December 2025
- Published by Springer Nature in Neurophysiology
- Vol. 57 (5-6) , 290-299
Effects of mild hypothermia on neuronal mitochondrial membrane potential and apoptosis in vivo and in vitro
- 1 December 2025
- Published by Springer Nature in Neurophysiology
- Vol. 57 (5-6) , 290-299
Effects of mild hypothermia on neuronal mitochondrial membrane potential and apoptosis in vivo and in vitro
- 23 February 2024
- Published by Elsevier in Brain Research
- Vol. 1831, 148826
Hypothermia promotes tunneling nanotube formation and the transfer of astrocytic mitochondria into oxygen-glucose deprivation/reoxygenation-injured neurons
- 23 February 2024
- Published by Elsevier in Brain Research
- Vol. 1831, 148826
Hypothermia promotes tunneling nanotube formation and the transfer of astrocytic mitochondria into oxygen-glucose deprivation/reoxygenation-injured neurons
- Open Access
- 6 April 2022
- Published by Springer Nature in Research Square
Goal-directed fluid therapy combined with dexmedetomidine precipitates neurological outcomes in patients undergoing surgery for traumatic brain injury A randomised controlled trial
Background Dexmedetomidine is a new type of highly selective α2- adrenergic receptor agonist, which is commonly used in clinical anesthesia. It has been found that dexmedetomidine can protect the brain of patients with traumatic brain injury. At present, there is no report of compound dexmedetomidine for traumatic brain injury patients who receive goal-oriented liquid therapy. This study was to evaluate the effect of goal-directed fluid therapy combined (GDFT) strategy combined with dexmedetomidine on neurological outcomes in patients with traumatic brain injury (TBI) surgery. Methods One hundred-twenty patients with TBI were randomly divided into four groups: control group, GDFT group, dexmedetomidine group and GDFT with dexmedetomidine group. Perioperative transfusion volume and hemodynamics, Glasgow outcome scale (GOS) and postoperative length of hospital stay were recorded. Cerebral oxygen metabolism indexes and biomarkers for brain injury were determined. Results GDFT combined with dexmedetomidine decreased perioperative total transfusion volume including crystalloid and colloidal solution volume than dexmedetomidine group. Combination therapy of GDFT + dexmedetomidine decreased jugular bulb lactate than that at end of the surgery in control group, and had higher SjvO2, lower Da-jvO2 and CERO2 than that at end of the surgery in GDFT group and dexmedetomidine group. Combination therapy of GDFT + dexmedetomidine decreased serum concentrations of S100β protein and neuron-specific enolase than that at end of the surgery in GDFT group and dexmedetomidine group, and had a higher GOS and a shorter length of hospital stay than the control group. Conclusions Our findings indicate that GDFT combined with dexmedetomidine allows a better-optimized fluid therapy strategy and improves neurological outcomes in patients undergoing surgery for TBI.
- 6 April 2022
- Published by Springer Nature in Research Square
Open AccessGoal-directed fluid therapy combined with dexmedetomidine precipitates neurological outcomes in patients undergoing surgery for traumatic brain injury A randomised controlled trial
Background Dexmedetomidine is a new type of highly selective α2- adrenergic receptor agonist, which is commonly used in clinical anesthesia. It has been found that dexmedetomidine can protect the brain of patients with traumatic brain injury. At present, there is no report of compound dexmedetomidine for traumatic brain injury patients who receive goal-oriented liquid therapy. This study was to evaluate the effect of goal-directed fluid therapy combined (GDFT) strategy combined with dexmedetomidine on neurological outcomes in patients with traumatic brain injury (TBI) surgery. Methods One hundred-twenty patients with TBI were randomly divided into four groups: control group, GDFT group, dexmedetomidine group and GDFT with dexmedetomidine group. Perioperative transfusion volume and hemodynamics, Glasgow outcome scale (GOS) and postoperative length of hospital stay were recorded. Cerebral oxygen metabolism indexes and biomarkers for brain injury were determined. Results GDFT combined with dexmedetomidine decreased perioperative total transfusion volume including crystalloid and colloidal solution volume than dexmedetomidine group. Combination therapy of GDFT + dexmedetomidine decreased jugular bulb lactate than that at end of the surgery in control group, and had higher SjvO2, lower Da-jvO2 and CERO2 than that at end of the surgery in GDFT group and dexmedetomidine group. Combination therapy of GDFT + dexmedetomidine decreased serum concentrations of S100β protein and neuron-specific enolase than that at end of the surgery in GDFT group and dexmedetomidine group, and had a higher GOS and a shorter length of hospital stay than the control group. Conclusions Our findings indicate that GDFT combined with dexmedetomidine allows a better-optimized fluid therapy strategy and improves neurological outcomes in patients undergoing surgery for TBI.
- 1 September 2021
- Published by SAGE Publications in Therapeutic Hypothermia and Temperature Management
- Vol. 11 (3) , 155-163
Head Mild Hypothermia Exerts a Neuroprotective Role in Ischemia–Reperfusion Injury by Maintaining Glial Glutamate Transporter 1
Stroke is the second leading cause of death worldwide; nevertheless, its pathological mechanism still remains unclear. Besides, there is an urgent need to find new effective treatment strategies for patients with stroke. Hypothermia therapy is widely used in clinical as a neuroprotective strategy practice. However, the exact mechanism is not fully understood. In this study, we examined the effects of hypothermia on glial glutamate transport-1 (GLT-1) and the extracellular glutamate concentration ([Glu]e) in cerebral ischemia–reperfusion insult rats. Our results revealed that cerebral brain ischemia–reperfusion caused the decrease of GLT-1 and Bcl-2, the increase of Bax and [Glu]e, and caused neuron loss. On the contrary, head mild hypothermia (HMH) for 2 hours alleviated the abovementioned effects and exerted neuroprotection. In the hypothermia group, pretreatment with dihydrokainate, a functional antagonist of GLT-1 by lateral ventricle injection partly reversed the abovementioned effect of HMH. Our results suggest that HMH could exert a neuroprotective role by maintaining GLT-1 and reducing the excitotoxicity of [Glu]e during ischemia–reperfusion insult in rats.
- 1 September 2021
- Published by SAGE Publications in Therapeutic Hypothermia and Temperature Management
- Vol. 11 (3) , 155-163
Head Mild Hypothermia Exerts a Neuroprotective Role in Ischemia–Reperfusion Injury by Maintaining Glial Glutamate Transporter 1
Stroke is the second leading cause of death worldwide; nevertheless, its pathological mechanism still remains unclear. Besides, there is an urgent need to find new effective treatment strategies for patients with stroke. Hypothermia therapy is widely used in clinical as a neuroprotective strategy practice. However, the exact mechanism is not fully understood. In this study, we examined the effects of hypothermia on glial glutamate transport-1 (GLT-1) and the extracellular glutamate concentration ([Glu]e) in cerebral ischemia–reperfusion insult rats. Our results revealed that cerebral brain ischemia–reperfusion caused the decrease of GLT-1 and Bcl-2, the increase of Bax and [Glu]e, and caused neuron loss. On the contrary, head mild hypothermia (HMH) for 2 hours alleviated the abovementioned effects and exerted neuroprotection. In the hypothermia group, pretreatment with dihydrokainate, a functional antagonist of GLT-1 by lateral ventricle injection partly reversed the abovementioned effect of HMH. Our results suggest that HMH could exert a neuroprotective role by maintaining GLT-1 and reducing the excitotoxicity of [Glu]e during ischemia–reperfusion insult in rats.
- 1 June 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 756, 135940
Mild hypothermia facilitates mitochondrial transfer from astrocytes to injured neurons during oxygen-glucose deprivation/reoxygenation
- 1 June 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 756, 135940
Mild hypothermia facilitates mitochondrial transfer from astrocytes to injured neurons during oxygen-glucose deprivation/reoxygenation
- Open Access
- 18 January 2021
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 32 (4) , 312-320
Mild hypothermia protects rat cortical neurons against oxygen-glucose deprivation/reoxygenation injury via the PI3K/Akt pathway
Ischemic stroke is the most frequent cause of long-term morbidity and mortality in the elderly worldwide. Mild hypothermia (32–35°C) has been found to have a neuroprotective effect against ischemic stroke. However, the protective mechanisms remain unclear. In the present study, we explore the neuroprotective effect of mild hypothermia in neuron-astrocyte cocultures by oxygen-glucose deprivation/reoxygenation (OGD/R) as well as the underlying mechanisms. Thionin staining was performed and cell viability, extracellular glutamate concentration and the phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) pathway-related proteins were detected after OGD/R. The results indicated that mild hypothermia significantly alleviated damage to Nissl bodies and increased the viability of neurons, which alleviated OGD/R-triggered neuronal injury. Furthermore, mild hypothermia significantly enhanced the phosphorylation of Akt (pAkt) and glutamate transporter-1 (GLT-1) and reduced extracellular glutamate concentration after OGD/R. When the PI3K inhibitor LY294002 was added, neuronal viability and the expression of pAkt and GLT-1 decreased, and extracellular glutamate concentration increased. The protective effect of mild hypothermia was counteracted by LY294002. There was no significant change in neuronal viability or the expression of pAkt and GLT-1 in the group treated with dihydrokainate, an inhibitor of GLT-1-function, compared with the mild hypothermia + OGD/R (HOGD) group, but extracellular glutamate concentration was increased. Consequently, mild hypothermia promoted glutamate clearance by regulating GLT-1 expression via the PI3K/Akt pathway, providing a neuroprotective effect against OGD/R injury.
- 18 January 2021
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 32 (4) , 312-320
Open AccessMild hypothermia protects rat cortical neurons against oxygen-glucose deprivation/reoxygenation injury via the PI3K/Akt pathway
Ischemic stroke is the most frequent cause of long-term morbidity and mortality in the elderly worldwide. Mild hypothermia (32–35°C) has been found to have a neuroprotective effect against ischemic stroke. However, the protective mechanisms remain unclear. In the present study, we explore the neuroprotective effect of mild hypothermia in neuron-astrocyte cocultures by oxygen-glucose deprivation/reoxygenation (OGD/R) as well as the underlying mechanisms. Thionin staining was performed and cell viability, extracellular glutamate concentration and the phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) pathway-related proteins were detected after OGD/R. The results indicated that mild hypothermia significantly alleviated damage to Nissl bodies and increased the viability of neurons, which alleviated OGD/R-triggered neuronal injury. Furthermore, mild hypothermia significantly enhanced the phosphorylation of Akt (pAkt) and glutamate transporter-1 (GLT-1) and reduced extracellular glutamate concentration after OGD/R. When the PI3K inhibitor LY294002 was added, neuronal viability and the expression of pAkt and GLT-1 decreased, and extracellular glutamate concentration increased. The protective effect of mild hypothermia was counteracted by LY294002. There was no significant change in neuronal viability or the expression of pAkt and GLT-1 in the group treated with dihydrokainate, an inhibitor of GLT-1-function, compared with the mild hypothermia + OGD/R (HOGD) group, but extracellular glutamate concentration was increased. Consequently, mild hypothermia promoted glutamate clearance by regulating GLT-1 expression via the PI3K/Akt pathway, providing a neuroprotective effect against OGD/R injury.